Rick has 36 years of senior executive leadership experience in the medical device industry.

Most recently, Rick served as Chairman of the Board and CEO of ConvaTec PLC, a FTSE 250 Company, where he had previously served as an Independent Director of the Board.

Prior to founding Revival Healthcare Capital, Rick served as a Managing Director at PTV Healthcare Capital. Prior to that, Rick was Company Group Chairman, Johnson & Johnson, and Worldwide Franchise Chairman, Cordis Corporation. Rick also served as President of Cordis Corporation and was previously Worldwide Franchise Vice President of Centocor, Inc., which merged with Johnson & Johnson in 1999. Rick was part of the launch of the world’s first drug eluting stent, the CYPHER® Sirolimus-eluting Coronary Stent. Before joining Johnson & Johnson, Rick served at Racal HealthCare, Inc., where he was Vice President, Global Marketing and prior to that, he spent a decade with Boehringer Mannheim Pharmaceuticals and Allergan Pharmaceuticals in various U.S. and global sales, sales management, and marketing management roles.

Rick holds a B.B.A. in Marketing from Mississippi State University. He served five years in the U.S. Army where he obtained the rank of captain. Rick serves as a Texas Health Catalyst Advisory Panel Member for The University of Texas Dell Medical School and previously as a Strategic Advisory Group Member for Nikon Corporation. Rick is also a member of the Economic Advisory Board of Mississippi State University, and a consultant member of the Society for Cardiovascular Angiography and Interventions, and he has worked within the industry to shape global education of interventional specialties. He participates in the AdvaMed Venture Capital Advisory Council and the Dartmouth Device Development (3D) Symposium Executive Committee, and he is a member of the Accelerated Innovation Program Working Group for the National Heart Lung and Blood Institute (NHLBI).

Rick currently serves on the boards of Augmedics, Distalmotion, and Kardion, Revival portfolio companies, in addition to Silk Road Medical. He also serves on the Executive Advisory Board of L.E.K. Consulting, a healthcare consulting firm. He previously served as an Independent Director at Apollo Endosurgery; as an Independent Director on ConvaTec PLC, a FTSE 250 company; a Director at Cardiologs prior to its acquisition by Phillips in January 2022; Chairman of the Board for Cardiva Medical; a Director for Intersect ENT before the company went public in July 2014; a Director at Corventis prior to its acquisition by Medtronic in June 2014; a Director at Cameron Health prior to its acquisition by Boston Scientific in June 2012; and Chairman of the Board for IDEV Technologies prior to its acquisition by Abbott in August 2013. He also previously served as a Director of Insite Vision and Chairman of the Board for Tryton Medical.

Lauren has over 16 years of financial leadership and private equity experience in the medical device industry.

Prior to founding Revival, Lauren served as Partner and Director of Operations at PTV Healthcare Capital, where she served on the investment committee and worked with the investment team on sourcing, evaluating and structuring new investments in addition to directing fund administration including investor relations, finance, accounting, and compliance and oversight of day-to-day operations. Prior to her role as Partner and Director of Operations, Lauren served as Finance Manager at PTV. Recently, Lauren led a strategic planning workstream at ConvaTec Group PLC. Most recently, Lauren also served as the interim Chief Financial Officer for a Texas-based owner and operator of four memory care communities with an innovative Montessori approach to caring for people living with Alzheimer’s and other forms of dementia.

Lauren serves as an observer on the Board of Directors for Distalmotion, Kardion and Metavention, Revival portfolio companies, and on the Jon Brumley Texas Venture Labs Advisory Council. She previously was an observer on the Board of Directors for Cardiva Medical and a Director on the Board for the Ann Richards School Foundation, an organization focused on advancing education and empowering young women leaders where she chaired the Ann Richards School Foundation Investment Committee and served on the Finance Committee. Lauren was an organizing member of ATX MedTech Women and she previously served in the Dell Medical School Society for Health & Business, the Private Equity Women Investor Network, and The Junior League of Austin. In 2017, Lauren was recognized as an Austin Under 40 Awards Winner in the Healthcare and Life Sciences Category, a distinction that recognizes leadership in one’s respective industry as well as a strong commitment to serving the Austin Community. In 2016, Lauren was selected as a finalist for the Austin Under 40 Awards, also in the Healthcare and Life Sciences Category. In 2015, Lauren was recognized by the Austin Business Journal as a Profiles in Power Rising Star Finalist, a distinction that celebrates women under 30 for their achievements in business and contributions to the community thus far.

Lauren graduated with high honors from the McCombs School of Business at The University of Texas at Austin and holds a B.B.A. in Finance.

Justin Ballotta has over 25 years of experience in the medical device industry spanning product design and development, clinical, quality, marketing and manufacturing.

Prior to co-founding Revival, Justin was the Chief Operating Officer at Cardiva Medical, acquired by Haemonetics in January 2021 for $510 million. Justin joined Cardiva, a PTV Healthcare Capital portfolio company, in June 2010 where he was responsible for Product Development, Manufacturing, Supply Chain, Quality, Clinical and Regulatory Affairs and Customer Operations.

While at Cardiva, Justin led the approval of two PMA-track vascular closure devices and completed several multi-center, prospective clinical trials focused on clinical efficacy and economic value. Justin’s PMA and clinical trials efforts at Cardiva led to the first multi-vessel closure system for cardiac ablation procedures and achieved the first labeling for same day discharge for these procedures. In 2018, Justin led the building of a new offshore manufacturing facility that was recipient of the prestigious Shingo Award for manufacturing and operational excellence in 2018.

Prior to Cardiva, Justin spent 12 years at Johnson & Johnson with increasing senior leadership roles ultimately leading to responsibility for new business assessments and strategic marketing for next generation structural heart and drug-eluting stents. While at Johnson & Johnson subsidiary, Cordis Corporation, Justin was the General Manager for the Cardiovascular Technologies (CVT) business unit where he was responsible for global product development and commercialization in both the US and the EU (Netherlands). Preceding this leadership role, Justin spent three years in the Netherlands leading research and development for coronary stent delivery systems and PTCA catheters. In 2000, Justin was a technical leader for the Checkmate System, the first brachytherapy device to utilize gamma radiation for the treatment of in-stent restenosis.

Justin co-founded Bio-Trainers, LLC; a company that focused on scanning technology of human cadavers for the development of surgical training tools, namely ACL and MCL repair and was funded with NIH grants.

Justin currently serves as a Director on the Board for Kardion and as an Observer on the Boards of Distalmotion and Metavention, Revival portfolio companies.

He holds a B.S. in Biomedical & Mechanical Engineering from the University of Miami, an M.S. in Engineering Management from Florida International University and an MBA from both the Columbia Business School and the Haas School of Business at University of California Berkeley.

Todd M. Pope brings 33 years of technology, medical device, and leadership experience across large cap and start-up MedTech. His last 20 years have been in CEO roles of both private and public companies.

Todd serves as the Chairman of the Board of Directors of AdvaMed ACCEL. Todd was most recently the President and CEO, of WellAir, a healthy indoor air solutions provider which recently acquired UV Innovators, where Todd served as executive chairman. Prior to joining WellAir, Todd was a Revival Resident Operating Partner.

Before UV Innovators, Todd was the President and CEO of TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that digitizes the interface between the surgeon and the patient to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options.

Todd’s previous roles included Global President of Johnson & Johnson Cordis; where he led a multi-billion-dollar business unit comprised of 3 distinct companies; Cardiology, Neurovascular, and Peripheral Vascular. Todd has also held various executive positions, including Liquidia Technologies' CEO, a nanotechnology-based healthcare company, in Research Triangle Park, North Carolina.

He served 14 years in various management roles at Johnson & Johnson's Ethicon Endo-Surgery Division and Boston Scientific, where he rose to Vice President, Global Sales, and Marketing, Neurovascular Division.

In addition to serving as Chairman of the Board of Directors of AdvaMed ACCEL, Todd is also on the board of directors of Distalmotion, a Revival portfolio company; Humacyte, a regenerative medicine company leveraging a scalable technology platform to develop bioengineered human tissues. He serves on the Educational Foundation for the University of North Carolina at Chapel Hill, where he is the immediate past Executive Chairman of the Board. He was named to TIME Magazine’s 2018 list of 50 Most Influential People in Health Care.

Alex Forshey has 16 years of experience in banking and investments.

Most recently, Alex worked with the corporate development team of ConvaTec Group PLC, a global medical products and technologies company, where led a portfolio review and strategic alternatives analysis. Prior to ConvaTec, Alex worked as an Associate in the M&A group at Barclays in Houston where he focused on valuation, structuring and execution of mergers, acquisitions, and divestitures as well as structured transactions and strategic alternatives analysis.

Prior to Barclays, Alex was the Senior Analyst for Cockrell Interests, a diversified investment company, where he worked with the investment committee on sourcing, evaluating and executing new investment opportunities. While at Cockrell, Alex focused on direct public and private equity and debt investments across sectors including healthcare, oil and gas, real estate and consumer products. Additionally, Alex worked with Cockrell’s real estate team on the financial analysis of several large direct real estate and infrastructure development projects, and with the PTV Healthcare team to analyze potential investments by Cockrell into certain deals.

Alex holds an MBA from Rice University and is a Jones Scholar. Alex graduated Magna Cum Laude from the Mays School of Business at Texas at A&M University with a B.B.A. in Finance. He serves as an observer on the Board of Directors for Augmedics. Alex also serves as a member of the Houston Board for Kickstart Kids, an organization focused on providing students the tools and support necessary to achieve success by developing character through martial arts.

Lisa Rainone has over 14 years of finance and operational experience in the private equity and commercial real estate industries and has extensive experience in fund administration and investor relations.

Recently, Lisa played a role in the facilitation of ConvaTec Group PLC’s Pivot to Growth strategy, including supporting strategy planning and development, corporate communications analysis, and investor relations execution. Most recently, Lisa was integral to the fundraising of RVLHC II, a $500 million fund dedicated to pursuing strategic growth partnerships in the medical device and diagnostics sector.

Prior to Revival, Lisa managed fund administration and investor relations at PTV Healthcare Capital. In addition, she coordinated the planning of investor events, including semi-annual Fund Advisory Board meetings, and directly supported PTV’s involvement in industry conferences including the JP Morgan Healthcare Conference and Austin’s own South by Southwest (SXSW).

Earlier in her career, Lisa spent seven years at The Irvine Company, the largest land development firm in California. She was part of bringing office property management in-house and in the development of the Energy Management Department, which provides enterprise-wide energy management to TIC’s diverse portfolio of 100 MSF of commercial office, retail, resort and multifamily holdings.

Lisa holds a Bachelor of Business Administration from the University of San Diego School of Business.

Clay has over 13 years of finance and investment experience, most recently serving as Portfolio Manager and Vice President with Ovation Partners, an alternative private investment fund in Austin, Texas, for four years.

While at Ovation, Clay negotiated, structured, and managed senior and subordinated debt investments as well as equity investments across a wide range of industries and entity types. Upon investment execution, Clay served as a resource and consultant for his portfolio company management teams. Prior to Ovation Partners, Clay served as Senior Associate at PTV Healthcare Capital, a medtech-focused venture and growth equity firm in Austin. Clay also held responsibility for the evaluation and maintenance of new investment opportunities, guiding pitch meetings, leading due diligence efforts, as well as presenting to PTV’s investor base annually with a focus on medtech market trends, fund performance, and target investment markets. In addition to his deal-side responsibilities, Clay held responsibility for calculating quarterly portfolio company valuations and preparing financial statements for the PTV funds, managing financial statement audits, and maintaining investment returns reporting.

Clay is a CPA in Texas and commenced his career at Ernst & Young in Austin, where he audited both public and private companies as well as investment funds in the software, real estate, technology, manufacturing, and natural resources industries.

Clay received his Masters and Bachelors degrees in Accounting with a Minor in Finance from the McCombs School of Business at The University of Texas at Austin where he graduated with honors.

Samuel (Sam) M. Liang is a global healthcare executive with 39 years of diverse senior leadership experience in the medical device, pharma, clinical service and payer sectors.

Sam brings a multinational perspective to healthcare, offering valuable, strategic insights from all sides of the equation, including the payer world. He has led companies through organizational and cultural transformations, M&A, and progressive improvements in both the patient and employee experience. He serves as an independent director for Health Plus Management and is an advisor to the University of Texas Dell Medical School Texas Health Catalyst program.

Sam retired at year-end 2020 from Hanger, Inc. (NYSE: HNGR), where he served over six years as President of Hanger Clinic. Prior to Hanger, Sam spent 2010-2014 with Bayer Healthcare as President & CEO of MEDRAD and Head of the Radiology & Interventional business. Sam also ran a start-up, Vascular Therapies, from 2008-2010 as President & CEO where he developed the initial business plans, raised early seed capital and recruited key talent for a drug/device surgical product.

From 1984-2008, Sam held a career at Cordis and J&J, working in diverse functions, geographies and businesses earning roles with increasing responsibilities. Starting as an engineer, he developed several products, set up factories in Asia and then managed Cordis’ interests in Asia Pacific. At J&J, Sam ran Cordis’ Cardiology Stent franchise, Endovascular and Neurovascular businesses. Sam was part of the global launch of Cypher, the world’s first drug eluting stent.

Sam holds a B.S.E. in Mechanical Engineering and Material Sciences from Duke University, an M.B.A. from the Kellogg Graduate School of Management at Northwestern University and is currently a candidate for Directorship Certification with the National Association of Corporate Directors’ Accelerate program.

John Russell is a 35+ year medical device industry leader and CEO, who has led in the creation and rapid adoption of numerous breakthroughs for patients in the fields of cardiac medical devices and digital health.

From 2010 to 2021, John was CEO and board member of two consecutive venture-backed companies. Most recently, John was CEO of Cardiva Medical, where he led the company to develop the first multi-vessel closure system for cardiac ablation procedures, and achieve the first labeling for same day discharge for these procedures. Cardiva was acquired by Haemonetics in 2021 for $510 million. Prior to Cardiva, John was CEO of Corventis, Inc – which developed the industry’s first wearable and wireless cardiac monitoring patch. Corventis was acquired by Medtronic in 2014 for $130 million.

Before his private company experience, John held senior level positions with Guidant / Boston Scientific in their Cardiac Rhythm Management (CRM) division where he was head of US CRM sales. Prior to that he was general manager of the LATITUDE Patient Management business and was also head of new product planning.

Earlier in his career, John held the roles of sales representative, regional sales manager, and sales director with Guidant CRM – during introduction of the first transvenous implantable defibrillators and the first cardiac resynchronization therapy devices. He was also a research and development engineer for Edwards Lifesciences.

John holds a BS in mechanical engineering from Duke University and an MBA from the University of North Carolina, Chapel Hill.

An accomplished executive with a career spanning over 34 years in medical diagnostics, devices and digital health, Tim’s background includes extensive experience in raising capital as well as designing and implementing highly focused commercial/business development strategies within both large and small companies.

Tim is currently Chairman and CEO of TSTILL Enterprises LLC, and an Operating Partner with Revival Healthcare Capital, where he is involved in evaluating and managing compelling investment opportunities in medical technology.

Tim has been directly responsible for building the commercial viability at all of his previous companies – many of which have been successfully acquired. His most recent operating role was President and CEO of Sense Biodetection. Early in 2023, Sense Bio was merged with Sherlock Biosciences to create a leading point of care diagnostics company serving the consumer diagnostics market.

Prior to Sense Biodetection, Tim has been a CEO and Board member at numerous medical technology companies: Myoscience, MDx Health (Board member), Gold Standard Diagnostics (Executive Chairman), Global Kinetics, Xagenic and Accumetrics. Earlier in his career, Tim also held senior leadership roles at HemoSense, Cholestech, Boehringer Mannheim & Roche.

Tim has a master’s degree in business administration (Dean’s Scholar) from the University of Southern California, and a Bachelor of Science degree (Highest Honors) from the University of California at Davis.

Kyndal Wagner has almost 10 years of experience as a problem solver and enabler of organizational effectiveness.

Kyndal joined Revival in March 2022 after a successful career teaching middle school mathematics. Kyndal taught at Central Magnet School in Murfreesboro, TN, the #1 ranked public school in the state of Tennessee and a Top 20 school in the country. During her teaching career, Kyndal was the head coach for Central Magnet’s Middle and High School swim teams, a role for which she was awarded Coach of the Year during her tenure.

Kyndal graduated from Clemson University where she was an education major and spent a year as a member of the Clemson Women’s Rowing team. She later obtained a Masters Degree in Education with a specialty in Math from Middle Tennessee State University.             

Kyndal brings a strong organizational acumen to the team, which she combines with a calm presence to keep the team on track. She has quickly established effective operational support across the complete Revival team.